READOUT / FREQUENT QUESTIONS
CJC-1295, answered: status, safety, the two variants, and the research.
Direct answers to the questions people actually ask about CJC-1295, each one cited where it makes a quantitative claim. This page is the index; the topic pages carry the full readouts.
CJC-1295 frequently asked questions
Each question below is answered directly from the published research and regulatory record. Where an answer states a number, it cites the study behind it. For the full context, follow the linked topic pages.
What is CJC-1295?
A synthetic long-acting analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions [1]. The DAC variant adds a covalent serum-albumin link for a multi-day half-life; the no-DAC "Modified GRF 1-29" form is short-acting [1][11].
What does CJC-1295 do?
In published research it binds the pituitary GHRH receptor and drives synthesis and pulsatile release of growth hormone, which raises hepatic IGF-1 [1][2]. Human pharmacokinetic studies showed dose-dependent, multi-day elevation of GH and IGF-1 [1][3].
Is CJC-1295 a steroid?
No. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that acts on the pituitary GHRH receptor; it is not an anabolic-androgenic steroid [1]. It is an unapproved research chemical, not approved for human use.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA, or any major regulator, for human use; it is handled as a research chemical. The 2024 FDA Pharmacy Compounding Advisory Committee reviewed it and did not recommend it for the 503A compounding bulks list [10].
What did the 2024 FDA Pharmacy Compounding Advisory Committee say about CJC-1295?
FDA briefing materials for the 2024 PCAC meeting reviewed GH secretagogues including CJC-1295 and cited immunogenicity and other safety concerns as part of the basis for not recommending it for the 503A compounding bulks list [10].
What is CJC-1295's WADA status for tested athletes?
CJC-1295 is prohibited at all times — in and out of competition — under Section S2 of the WADA Prohibited List, which bans growth-hormone-releasing factors and their analogs. Detection assays (LC-MS/MS, immuno-PCR) are well established [6].
Why does the FDA cite immunogenicity as a concern for CJC-1295?
Peptide-albumin conjugates can in principle provoke an immune response. FDA briefing materials for the 2024 PCAC flagged immunogenicity, alongside other safety concerns, for GH secretagogues including CJC-1295 [10]. Long-term human safety data are lacking.
Is CJC-1295 safe?
Human safety data are limited to early pharmacokinetic studies; there are no long-term safety trials [1][3]. Theoretical concerns include fluid retention, effects on insulin sensitivity, and IGF-1 elevation, which epidemiology links to a modestly higher risk of some cancers [9]. It is unapproved for human use.
How much CJC-1295 should I take?
There is no approved human dose. Published human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram in research settings [1][3]. Online "protocols" are not derived from controlled human trials.
How much CJC-1295 DAC should I take?
No approved human dose exists. Human pharmacokinetic work with the DAC variant used 30 to 90 micrograms per kilogram subcutaneously [1][3]; its multi-day half-life (5.8 to 8.1 days) means exposure persists far longer than the short-acting no-DAC form [1].
What is CJC-1295 with DAC?
CJC-1295 "with DAC" (Drug Affinity Complex) carries a maleimidopropionyl handle that covalently binds the free thiol on serum albumin, forming a peptide-albumin conjugate with a multi-day plasma half-life [1][2].
What is CJC-1295 DAC?
The DAC ("Drug Affinity Complex") variant of CJC-1295 conjugates to circulating albumin via Michael addition, extending the half-life toward that of albumin itself, so a single dose elevates GH and IGF-1 for days [1][2].
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [8]. Oral bioavailability is negligible; subcutaneous injection is the route used in studies [1]. This is descriptive of laboratory handling, not a use instruction.
Where to inject CJC-1295?
Published research used subcutaneous injection as the primary route; early GRF(1-29) pharmacokinetic work also used intravenous administration [1][2]. The literature describes the route studied; it does not establish a safe human-use protocol.
How much CJC-1295 / ipamorelin should I take?
There is no controlled-trial human dose for the combination. The pairing rests on a two-receptor rationale — a GHRH analog plus a GHRP — but circulating combination "protocols" are not derived from published efficacy trials [1].
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs act through distinct receptors and can synergize to release more GH than either alone [1]. There are no controlled human efficacy trials of the specific CJC-1295/ipamorelin combination for body-composition outcomes.
What is CJC-1295 ipamorelin?
A commonly discussed research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin), combined for their complementary, two-pathway effect on growth-hormone release [1]. It is not a studied therapeutic regimen.
Are CJC-1295 peptides safe?
Published human exposure is limited to early pharmacokinetic studies; long-term safety is unestablished, and the compound is unapproved [1][3]. Reported and theoretical concerns include fluid retention, insulin-sensitivity effects, immunogenicity, and IGF-1-related cancer-risk questions [9][10].
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and is not a testosterone-raising agent. Published CJC-1295 studies focused on GH and IGF-1 [1][3]; they do not establish a direct effect on testosterone.
What are the side effects of CJC-1295?
There is no controlled long-term human safety dataset. GH-axis stimulation can cause fluid retention and edema and affect insulin sensitivity; sustained IGF-1 elevation raises theoretical cancer-risk questions [9], and FDA flagged immunogenicity for this class [10].
What to expect when taking CJC-1295?
This site describes research findings, not a use protocol. In studies, the compound produced dose-dependent, multi-day increases in GH and IGF-1 [1][3]; it is unapproved for human use, and outcomes in healthy adults are not established by controlled trials.
Does CJC-1295 lower testosterone?
Published CJC-1295 research targeted the GH/IGF-1 axis and did not report testosterone suppression as an effect [1][3]; there is no controlled evidence that CJC-1295 lowers testosterone.